1. Home
  2. IDAI vs ALLR Comparison

IDAI vs ALLR Comparison

Compare IDAI & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo T Stamp Inc.

IDAI

T Stamp Inc.

HOLD

Current Price

$3.81

Market Cap

20.9M

Sector

Technology

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.00

Market Cap

16.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDAI
ALLR
Founded
2016
2004
Country
United States
United States
Employees
N/A
7
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
16.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IDAI
ALLR
Price
$3.81
$1.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$12.00
$9.50
AVG Volume (30 Days)
127.5K
148.6K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,727,824.00
N/A
Revenue This Year
$3.46
N/A
Revenue Next Year
$219.85
N/A
P/E Ratio
N/A
N/A
Revenue Growth
72.57
N/A
52 Week Low
$1.43
$0.61
52 Week High
$18.75
$2.35

Technical Indicators

Market Signals
Indicator
IDAI
ALLR
Relative Strength Index (RSI) 48.08 37.75
Support Level $3.51 $1.05
Resistance Level $4.57 $1.18
Average True Range (ATR) 0.34 0.08
MACD -0.06 -0.01
Stochastic Oscillator 33.48 8.93

Price Performance

Historical Comparison
IDAI
ALLR

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

Share on Social Networks: